COVID-19 vaccine: AstraZeneca releases trial blueprint, aims for 50% effectiveness

Pharmaceutical giant AstraZeneca has released a 111-p blueprint for its COVID-19 vaccine Phase-3 trials where it has stated that company is aiming for a vaccine with 50 per cent effectiveness. AstraZeneca vaccine trials are currently underway in various parts of world such as United Kingdom, India and Brazil.

Pharma company plans early distribution for emergency use

AstraZeneca’s goal of developing a COVID-19 vaccine with 50 per cent effectiveness is same guidance for coronavirus vaccines that has been set by US Food and Drug Administration (FDA). Upon developing a vaccine that has required effect, pharma company is likely to halt early trials and seek approval for distributing of vaccine for emergency use.

US halts AstraZeneca's vaccine trail

AstraZeneca’s 111-p report comes after company was forced to pause its vaccine trial all over world after two of trials participants developed illnesses. AstraZeneca has t released much information about nature of illness but since n trail has resumed in UK after government got approval from Medicines Health Regulatory Authority (MHRA).

Read: Navajo Nation Report 12 New Coronavirus Cases, Deaths

Read: Reported Coronavirus Cases In Arkansas Rise By 549

Despite trial resuming in many or countries, AZD1222 which is being considered as a front runner for a potential COVID-19 vaccine has t been approved to resume trials in US. AstraZeneca’s vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adevirus) that causes infections in chimpanzees and contains genetic material of SARS-CoV-2 virus spike protein. 9 or pharma companies in world are currently in final phase of testing for a potential; coronavirus vaccine.

COVID-19 pandemic which saw its first outbreak in a wet market in Wuhan, China last year has w spread all across world. virus, named COVID-19 by World Health Organisation, has infected over 30 million people worldwide with global death toll reaching over 900,000.

Read: COVID-19 Vaccine: Serum Institute Gets DCGI d To Resume Phase Two, Three Trials

Read: AstraZeneca's COVID-19 Vaccine Trials Still On Hold In US Over Safety Concerns